Global Bladder Cancer Diagnostics Market Size, Trends and Growth Opportunity, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), By Stages (Stage I, Stage II, Stage III, and Stage IV), By Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), By End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales), By Region and forecast till 2030.

Report ID : AMR1004245 | Industries : Healthcare | Published On :December 2023 | Page Count : 219

Global Bladder Cancer Diagnostics Market Size, Trends and Growth Opportunity, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), By Stages (Stage I, Stage II, Stage III, and Stage IV), By Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), By End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales), By Region and forecast till 2030.

Global Bladder Cancer Diagnostics Market
Global Bladder Cancer Diagnostics Market was valued at USD 2.71 billion in 2022 and is slated to reach USD 8.79 billion by 2030 at a CAGR of 8.2% from 2023-2030.

The lining of the bladder contains healthy cells called urothelial cells, which typically alter and grow uncontrollably to form a mass known as a tumour. This is how bladder cancer develops. The urethra, ureters, and renal pelvis are all lined with urothelial cells. The term "upper tract urothelial cancer" is frequently used to refer to a kind of urothelial carcinoma that originates in the renal pelvis and ureters. It is typically treated similarly to how bladder cancer is, as discussed in this guide. Both malignant and benign tumours can exist. A malignant tumour is one that has cancer since it can develop and spread to different body sites. A benign tumour is one that has the potential to develop but not spread. There are very few benign bladder tumours.

Market Drivers
The majority of bladder cancer-related gene alterations are acquired rather than inherited before birth. Some of these acquired gene alterations are the result of radiation or chemical exposure that causes cancer. Tobacco smoke, for example, contains chemicals that can enter the bloodstream, be filtered by the kidneys, and then end up in urine where they can harm the cells in the bladder. The bladder may be exposed to other substances in the same way. Gene alterations, however, can occasionally just be arbitrary occurrences within a cell that have no external explanation. Older persons are more likely to develop bladder cancer. Nine out of ten patients with this malignancy are older than 55. People are typically 73 years old when they receive a diagnosis. The market for bladder cancer diagnostics is expanding as a result of the increasing number of bladder cancer cases in the general population and the increased use of bladder cancer diagnostic tools.

Market Restraints
Chemotherapy (often known as "chemo") involves anti-cancer medications that are typically administered intravenously (IV) or orally. Almost all parts of the body receive these medications after they enter the bloodstream. Many chemotherapy medications can't get past the bladder's defences and into the tumour cells, though. The most popular intravesical immunotherapy for the treatment of early-stage bladder cancer is Bacillus Calmette-Guerin (BCG). Although the BCG germ is linked to the one that causes TB, it typically doesn't cause significant illnesses. Through the use of a catheter, BCG is injected into the bladder, where it helps "turn on" the immune cells that then go on the attack against the bladder cancer cells. Chemotherapy medications may have negative effects. These depend on the medication kind, dosage, and length of treatment. The growth of the global bladder cancer diagnostics market is constrained by common side effects such as hair loss, mouth sores, loss of appetite, nausea and vomiting, diarrhoea, increased risk of infections (due to having too few white blood cells), easy bruising or bleeding (due to having too few blood platelets), and fatigue (due to having too few red blood cells, changes in metabolism, or other factors). A few chemotherapy medications can potentially have other, less typical side effects. For example, renal damage and hearing loss are possible side effects of cisplatin and carboplatin. In order to avoid the side effects from getting worse, it may occasionally be necessary to lower the dosage of the medication, postpone therapy, or discontinue it altogether. Therefore, the adverse effects of bladder cancer treatments such as medications and therapies may limit the development of the global market for bladder cancer diagnostics.

Impact of COVID-19
Many people have avoided going to hospitals and clinics because of the epidemic out of concern that they would contract the virus. This has caused a delay in bladder cancer diagnosis, which has affected the demand for diagnostic tests. As funds were allocated to combating the pandemic, healthcare spending decreased in several nations. The accessibility of diagnostic procedures and bladder cancer therapies has been impacted by this. The pandemic has sped up the introduction of telemedicine, allowing for patient monitoring and distant consultations. The demand for in-person diagnostic tests, such as those for bladder cancer, has been impacted by this.

Recent Development
Official Stratos Genomics acquisition by F. Hoffmann-La Roche Ltd. took place in May 2020. With this acquisition, the business will also work on DNA-based sequencing for diagnostic purposes. This has improved the business's healthcare diagnosing division and increased its ability to generate income.

The Binding Site Group, a market leader in specialised diagnostics, was acquired by Thermo Fisher Scientific Inc. in January 2023, according to an announcement made by the company. The segmentation of speciality diagnostics will benefit from the acquisition.

Market Segmentation
Global Bladder Cancer Diagnostics Market is segmented into Test Type, Stages, Cancer Type, End User and Distribution Channel. By Test Type such as Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, Others. By Stages such as Stage I, Stage II, Stage III, Stage IV. By Cancer Type such as Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types. By End User such as Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, Associated Labs. By Distribution Channel such as Direct Tender, Retail Sales.

Regional Analysis
Global Bladder Cancer Diagnostics Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. With the greatest market share, North America is anticipated to dominate the worldwide bladder cancer diagnostics market. This share is due to the presence of significant market players, including Koninklijke Philips N.V., Merck KGaA, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., and Bio-Rad Laboratories, Inc. The projection period in this region is expected to see market expansion driven by the increased prevalence of bladder cancer and enhanced imaging techniques.

Key Players
This report includes a list of numerous Key Players, namely F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, Canon Medical Systems Corporation, Siemens Healthcare GmbH, BD.

Market Taxonomy
By Test Type
• Cystoscopy
• Urine Lab Test
• Biopsy
• Imaging Test
• Others

By Stages
• Stage I
• Stage II
• Stage III
• Stage IV

By Cancer Type
• Transitional Cell Bladder Cancer
• Squamous Cell Bladder Cancer
• Other Cancer Types

By End User
• Hospital
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Independent Dignostic Laboratories
• Associated Labs

By Distribution Channel
• Direct Tender
• Retail Sales

By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa

Global Bladder Cancer Diagnostics Market

1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Bladder Cancer Diagnostics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Bladder Cancer Diagnostics Market, By Test Type
5.1 Y-o-Y Growth Comparison, By Test Type
5.2 Global Bladder Cancer Diagnostics Market Share Analysis, By Test Type
5.3 Global Bladder Cancer Diagnostics Market Size and Forecast, By Test Type
5.3.1 Cystoscopy
5.3.2 Urine Lab Test
5.3.3 Biopsy
5.3.4 Imaging Test
5.3.5 Others
6 Global Bladder Cancer Diagnostics Market, By Stages
6.1 Y-o-Y Growth Comparison, By Stages
6.2 Global Bladder Cancer Diagnostics Market Share Analysis, By Stages
6.3 Global Bladder Cancer Diagnostics Market Size and Forecast, By Stages
6.3.1 Stage I
6.3.2 Stage II
6.3.3 Stage III
6.3.4 Stage IV
7 Global Bladder Cancer Diagnostics Market, By Cancer Type
7.1 Y-o-Y Growth Comparison, By Cancer Type
7.2 Global Bladder Cancer Diagnostics Market Share Analysis, By Cancer Type
7.3 Global Bladder Cancer Diagnostics Market Size and Forecast, By Cancer Type
7.3.1 Transitional Cell Bladder Cancer
7.3.2 Squamous Cell Bladder Cancer
7.3.3 Other Cancer Types
8 Global Bladder Cancer Diagnostics Market, By Distribution Channel
8.1 Y-o-Y Growth Comparison, By Distribution Channel
8.2 Global Bladder Cancer Diagnostics Market Share Analysis, By Distribution Channel
8.3 Global Bladder Cancer Diagnostics Market Size and Forecast, By Distribution Channel
8.3.1 Direct Tender
8.3.2 Retail Sales
9 Global Bladder Cancer Diagnostics Market, By End user
9.1 Y-o-Y Growth Comparison, By End user
9.2 Global Bladder Cancer Diagnostics Market Share Analysis, By End user
9.3 Global Bladder Cancer Diagnostics Market Size and Forecast, By End user
9.3.1 Hospital
9.3.2 Diagnostic Imaging Centers
9.3.3 Cancer Research Institutes
9.3.4 Independent Dignostic Laboratories
9.3.5 Associated Labs
10 Global Bladder Cancer Diagnostics Market, By Region
10.1 Global Bladder Cancer Diagnostics Market Share Analysis, By Region
10.2 Global Bladder Cancer Diagnostics Market Share Analysis, By Region
10.3 Global Bladder Cancer Diagnostics Market Size and Forecast, By Region
11 North America Bladder Cancer Diagnostics Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Bladder Cancer Diagnostics Market Share Analysis, By Test Type
11.3 North America Bladder Cancer Diagnostics Market Size and Forecast, By Stages
11.4 North America Bladder Cancer Diagnostics Market Size and Forecast, By Cancer Type
11.5 North America Bladder Cancer Diagnostics Market Size and Forecast, By Distribution Channel
11.6 North America Bladder Cancer Diagnostics Market Size and Forecast, By End user
11.7 North America Bladder Cancer Diagnostics Market Size and Forecast, By Country
11.7.1 U.S.
11.7.1.1 Market Size and Forecast, By Test Type
11.1.1.2 Market Size and Forecast, By Stages
11.7.1.3 Market Size and Forecast, By Cancer Type
11.7.1.4 Market Size and Forecast, By Distribution Channel
11.7.1.5 Market Size and Forecast, By End user
11.7.2 Canada
11.7.2.1 Market Size and Forecast, By Test Type
11.1.2.2 Market Size and Forecast, By Stages
11.7.2.3 Market Size and Forecast, By Cancer Type
11.7.2.4 Market Size and Forecast, By Distribution Channel
11.7.2.5 Market Size and Forecast, By End user
11.7.3 Mexico
11.7.3.1 Market Size and Forecast, By Test Type
11.1.3.2 Market Size and Forecast, By Stages
11.7.3.3 Market Size and Forecast, By Cancer Type
11.7.3.4 Market Size and Forecast, By Distribution Channel
11.7.3.5 Market Size and Forecast, By End user
12 Europe Bladder Cancer Diagnostics Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Bladder Cancer Diagnostics Market Share Analysis, By Test Type
12.3 Europe Bladder Cancer Diagnostics Market Size and Forecast, By Stages
12.4 Europe Bladder Cancer Diagnostics Market Size and Forecast, By Cancer Type
12.5 Europe Bladder Cancer Diagnostics Market Size and Forecast, By Distribution Channel
12.6 Europe Bladder Cancer Diagnostics Market Size and Forecast, By End user
12.7 Europe Bladder Cancer Diagnostics Market Size and Forecast, By Country
12.7.1 Germany
12.7.1.1 Market Size and Forecast, By Test Type
12.1.1.2 Market Size and Forecast, By Stages
12.7.1.3 Market Size and Forecast, By Cancer Type
12.7.1.4 Market Size and Forecast, By Distribution Channel
12.7.1.5 Market Size and Forecast, By End user
12.7.2 France
12.7.2.1 Market Size and Forecast, By Test Type
12.1.2.2 Market Size and Forecast, By Stages
12.7.2.3 Market Size and Forecast, By Cancer Type
12.7.2.4 Market Size and Forecast, By Distribution Channel
12.7.2.5 Market Size and Forecast, By End user
12.7.3 UK
12.7.3.1 Market Size and Forecast, By Test Type
12.1.3.2 Market Size and Forecast, By Stages
12.7.3.3 Market Size and Forecast, By Cancer Type
12.7.3.4 Market Size and Forecast, By Distribution Channel
12.7.3.5 Market Size and Forecast, By End user
12.7.4 Russia
12.7.4.1 Market Size and Forecast, By Test Type
12.1.4.2 Market Size and Forecast, By Stages
12.7.4.3 Market Size and Forecast, By Cancer Type
12.7.4.4 Market Size and Forecast, By Distribution Channel
12.7.4.5 Market Size and Forecast, By End user
12.7.5 Italy
12.7.5.1 Market Size and Forecast, By Test Type
12.1.5.2 Market Size and Forecast, By Stages
12.7.5.3 Market Size and Forecast, By Cancer Type
12.7.5.4 Market Size and Forecast, By Distribution Channel
12.7.5.5 Market Size and Forecast, By End user
12.7.6 Spain
12.7.6.1 Market Size and Forecast, By Test Type
12.1.6.2 Market Size and Forecast, By Stages
12.7.6.3 Market Size and Forecast, By Cancer Type
12.7.6.4 Market Size and Forecast, By Distribution Channel
12.7.6.5 Market Size and Forecast, By End user
12.7.7 Rest of Europe
12.7.7.1 Market Size and Forecast, By Test Type
12.1.7.2 Market Size and Forecast, By Stages
12.7.7.3 Market Size and Forecast, By Cancer Type
12.7.7.4 Market Size and Forecast, By Distribution Channel
12.7.7.5 Market Size and Forecast, By End user
13 Asia Pacific Bladder Cancer Diagnostics Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Bladder Cancer Diagnostics Market Share Analysis, By Test Type
13.3 Asia Pacific Bladder Cancer Diagnostics Market Size and Forecast, By Stages
13.4 Asia Pacific Bladder Cancer Diagnostics Market Size and Forecast, By Cancer Type
13.5 Asia Pacific Bladder Cancer Diagnostics Market Size and Forecast, By Distribution Channel
13.6 Asia Pacific Bladder Cancer Diagnostics Market Size and Forecast, By End user
13.7 Asia Pacific Bladder Cancer Diagnostics Market Size and Forecast, By Country
13.7.1 China
13.7.1.1 Market Size and Forecast, By Test Type
13.7.1.2 Market Size and Forecast, By Stages
13.7.1.3 Market Size and Forecast, By Cancer Type
13.7.1.4 Market Size and Forecast, By Distribution Channel
13.7.1.5 Market Size and Forecast, By End user
13.7.2 Japan
13.7.2.1 Market Size and Forecast, By Test Type
13.7.2.2 Market Size and Forecast, By Stages
13.7.2.3 Market Size and Forecast, By Cancer Type
13.7.2.4 Market Size and Forecast, By Distribution Channel
13.7.2.5 Market Size and Forecast, By End user
13.7.3 India
13.7.3.1 Market Size and Forecast, By Test Type
13.7.3.2 Market Size and Forecast, By Stages
13.7.3.3 Market Size and Forecast, By Cancer Type
13.7.3.4 Market Size and Forecast, By Distribution Channel
13.7.3.5 Market Size and Forecast, By End user
13.7.4 South Korea
13.7.4.1 Market Size and Forecast, By Test Type
13.7.4.2 Market Size and Forecast, By Stages
13.7.4.3 Market Size and Forecast, By Cancer Type
13.7.4.4 Market Size and Forecast, By Distribution Channel
13.7.4.5 Market Size and Forecast, By End user
13.7.5 Australia
13.7.5.1 Market Size and Forecast, By Test Type
13.7.5.2 Market Size and Forecast, By Stages
13.7.5.3 Market Size and Forecast, By Cancer Type
13.7.5.4 Market Size and Forecast, By Distribution Channel
13.7.5.5 Market Size and Forecast, By End user
13.7.6 New Zealand
13.7.6.1 Market Size and Forecast, By Test Type
13.7.6.2 Market Size and Forecast, By Stages
13.7.6.3 Market Size and Forecast, By Cancer Type
13.7.6.4 Market Size and Forecast, By Distribution Channel
13.7.6.5 Market Size and Forecast, By End user
13.7.7 Singapore
13.7.7.1 Market Size and Forecast, By Test Type
13.7.7.2 Market Size and Forecast, By Stages
13.7.7.3 Market Size and Forecast, By Cancer Type
13.7.7.4 Market Size and Forecast, By Distribution Channel
13.7.7.5 Market Size and Forecast, By End user
13.7.8 Malaysia
13.7.8.1 Market Size and Forecast, By Test Type
13.7.8.2 Market Size and Forecast, By Stages
13.7.8.3 Market Size and Forecast, By Cancer Type
13.7.8.4 Market Size and Forecast, By Distribution Channel
13.7.8.5 Market Size and Forecast, By End user
13.7.9 Rest of Asia
13.7.9.1 Market Size and Forecast, By Test Type
13.7.9.2 Market Size and Forecast, By Stages
13.7.9.3 Market Size and Forecast, By Cancer Type
13.7.9.4 Market Size and Forecast, By Distribution Channel
13.7.9.5 Market Size and Forecast, By End user
14 Latin America Bladder Cancer Diagnostics Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Bladder Cancer Diagnostics Market Share Analysis, By Test Type
14.3 Latin America Bladder Cancer Diagnostics Market Size and Forecast, By Stages
14.4 Latin America Bladder Cancer Diagnostics Market Size and Forecast, By Cancer Type
14.5 Latin America Bladder Cancer Diagnostics Market Size and Forecast, By Distribution Channel
14.6 Latin America Bladder Cancer Diagnostics Market Size and Forecast Application
14.7 Latin America Bladder Cancer Diagnostics Market Size and Forecast, By Country
14.7.1 Brazil
14.7.1.1 Market Size and Forecast, By Test Type
14.7.1.2 Market Size and Forecast, By Stages
14.7.1.3 Market Size and Forecast, By Cancer Type
14.7.1.4 Market Size and Forecast, By Distribution Channel
14.7.1.5 Market Size and Forecast, By End user
14.7.2 Argentina
14.7.2.1 Market Size and Forecast, By Test Type
14.7.2.2 Market Size and Forecast, By Stages
14.7.2.3 Market Size and Forecast, By Cancer Type
14.7.2.4 Market Size and Forecast, By Distribution Channel
14.7.2.5 Market Size and Forecast, By End user
14.7.3 Colombia
14.7.3.1 Market Size and Forecast, By Test Type
14.7.3.2 Market Size and Forecast, By Stages
14.7.3.3 Market Size and Forecast, By Cancer Type
14.7.3.4 Market Size and Forecast, By Distribution Channel
14.7.3.5 Market Size and Forecast, By End user
14.7.4 Peru
14.7.4.1 Market Size and Forecast, By Test Type
14.7.4.2 Market Size and Forecast, By Stages
14.7.4.3 Market Size and Forecast, By Cancer Type
14.7.4.4 Market Size and Forecast, By Distribution Channel
14.7.4.5 Market Size and Forecast, By End user
14.7.5 Chile
14.7.5.1 Market Size and Forecast, By Test Type
14.7.5.2 Market Size and Forecast, By Stages
14.7.5.3 Market Size and Forecast, By Cancer Type
14.7.5.4 Market Size and Forecast, By Distribution Channel
14.7.5.5 Market Size and Forecast, By End user
14.7.6 Venezuela
14.7.6.1 Market Size and Forecast, By Test Type
14.7.6.2 Market Size and Forecast, By Stages
14.7.6.3 Market Size and Forecast, By Cancer Type
14.7.6.4 Market Size and Forecast, By Distribution Channel
14.7.6.5 Market Size and Forecast, By End user
14.7.7 Rest of Latin America
14.7.7.1 Market Size and Forecast, By Test Type
14.7.7.2 Market Size and Forecast, By Stages
14.7.7.3 Market Size and Forecast, By Cancer Type
14.7.7.4 Market Size and Forecast, By Distribution Channel
14.7.7.5 Market Size and Forecast, By End user
15 Middle East Bladder Cancer Diagnostics Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Bladder Cancer Diagnostics Market Share Analysis, By Test Type
15.3 Middle East Bladder Cancer Diagnostics Market Size and Forecast, By Stages
15.4 Middle East Bladder Cancer Diagnostics Market Size and Forecast, By Cancer Type
15.5 Middle East Bladder Cancer Diagnostics Market Size and Forecast, By Distribution Channel
15.6 Middle East Bladder Cancer Diagnostics Market Size and Forecast, By End user
15.7 Middle East Bladder Cancer Diagnostics Market Size and Forecast, By Country
15.7.1 Saudi Arabia
15.7.1.1 Market Size and Forecast, By Test Type
15.7.1.2 Market Size and Forecast, By Stages
15.7.1.3 Market Size and Forecast, By Cancer Type
15.7.1.4 Market Size and Forecast, By Distribution Channel
15.7.1.5 Market Size and Forecast, By End user
15.7.2 UAE
15.7.2.1 Market Size and Forecast, By Test Type
15.7.2.2 Market Size and Forecast, By Stages
15.7.2.3 Market Size and Forecast, By Cancer Type
15.7.2.4 Market Size and Forecast, By Distribution Channel
15.7.2.5 Market Size and Forecast, By End user
15.7.3 Egypt
15.7.3.1 Market Size and Forecast, By Test Type
15.7.3.2 Market Size and Forecast, By Stages
15.7.3.3 Market Size and Forecast, By Cancer Type
15.7.3.4 Market Size and Forecast, By Distribution Channel
15.7.3.5 Market Size and Forecast, By End user
15.7.4 Kuwait
15.7.4.1 Market Size and Forecast, By Test Type
15.7.4.2 Market Size and Forecast, By Stages
15.7.4.3 Market Size and Forecast, By Cancer Type
15.7.4.4 Market Size and Forecast, By Distribution Channel
15.7.4.5 Market Size and Forecast, By End user
15.7.5 South Africa
15.7.5.1 Market Size and Forecast, By Test Type
15.7.5.2 Market Size and Forecast, By Stages
15.7.5.3 Market Size and Forecast, By Cancer Type
15.7.5.4 Market Size and Forecast, By Distribution Channel
15.7.5.5 Market Size and Forecast, By End user
15.7.6 Rest of Middle East & Africa
15.7.6.1 Market Size and Forecast, By Test Type
15.7.6.2 Market Size and Forecast, By Stages
15.7.6.3 Market Size and Forecast, By Cancer Type
15.7.6.4 Market Size and Forecast, By Distribution Channel
15.7.6.5 Market Size and Forecast, By End user
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 F. Hoffmann-La Roche Ltd
17.1.1 Overview
17.1.2 Offerings
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2 Merck KGaA
17.2.1 Overview
17.2.2 Offerings
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3 Thermo Fisher Scientific Inc
17.3.1 Overview
17.3.2 Offerings
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 Koninklijke Philips N.V
17.4.1 Overview
17.4.2 Offerings
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 Bio-Rad Laboratories, Inc.
17.5.1 Overview
17.5.2 Offerings
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 Agilent Technologies, Inc.
17.6.1 Overview
17.6.2 Offerings
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 FUJIFILM Corporation
17.7.1 Overview
17.7.2 Offerings
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 Canon Medical Systems Corporation
17.8.1 Overview
17.8.2 Offerings
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 Siemens Healthcare GmbH
17.9.1 Overview
17.9.2 Offerings
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 BD
17.10.1 Overview
17.10.2 Offerings
17.10.3 Key Financials
17.10.4 Business Segment & Geographic Overview
17.10.5 Key Market Developments
17.10.6 Key Strategies